What's new

Human medicines European public assessment report (EPAR): Ituxredi, rituximab, Date of authorisation: 19/09/2024, Status: Authorised

Human medicines European public assessment report (EPAR): Ituxredi, rituximab, Date of authorisation: 19/09/2024, Status: Authorised

Feb 10, 2025 - 16:48
 0
Human medicines European public assessment report (EPAR): Ituxredi, rituximab, Date of authorisation: 19/09/2024, Status: Authorised
Human medicines European public assessment report (EPAR): Ituxredi, rituximab, Date of authorisation: 19/09/2024, Status: Authorised
Read More

Tags:

Previous Article

STAT+: A check-in on health insurers’ medical costs, and more babies are being born

Next Article

Another Fastned Year of Fast Growth

Related Posts

Human medicines European public assessment report (EPAR): Ponvory, ponesimod, Date of authorisation: 19/05/2021, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 9, 2025  0

Orphan designation: Humanised monoclonal antibody targeting B-cell maturation antigen conjugated with maleimidocaproyl monomethyl auristatin F Treatment of multiple myeloma, 16/10/2017 Withdrawn

Orphan designation: Humanised monoclonal antibody targe...

Feb 19, 2025  0

Human medicines European public assessment report (EPAR): Eptifibatide Accord, eptifibatide, Date of authorisation: 11/01/2016, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 25, 2025  0